drugset / Trial / NCT01674647
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
RandomizedParallel-groupOpen-labelPrevention
Summary
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure common medical outcomes for this type of patient such as bleeding and stroke.
Timeline
- Start
- 2012-10
- Primary completion
- 2014-01
- Completion
- 2014-01
Publications
- Background Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367. Epub 2014 Sep 2.
- Background Hai Z, Guangrui S. Cardiac paraganglioma. Eur Heart J. 2018 Jun 14;39(23):2219. doi: 10.1093/eurheartj/ehu241. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluindione | Small molecule | — | Oral |
| Comparator | Phenprocoumon | Small molecule | — | Oral |
| Subject | Rivaroxaban | Other / unclassified | 15 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Comparator | Warfarin | Small molecule | — | Oral |
| Comparator | acenocoumarol | Unknown | — | Oral |